<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01338311</url>
  </required_header>
  <id_info>
    <org_study_id>BMC 10-226</org_study_id>
    <nct_id>NCT01338311</nct_id>
  </id_info>
  <brief_title>Salbutamol Tolerance Onset</brief_title>
  <official_title>Salbutamol: Tolerance to Bronchoprotection vs. Methacholine: Time Course of Onset</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Saskatchewan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Saskatchewan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Overuse of inhaled bronchodilator beta agonist medication results in a loss of effectiveness
      (i.e. tolerance). This has been shown for the short acting beta agonist salbutamol and the
      long acting beta agonist salmeterol. Tolerance to salmeterol is present within 24 hours. The
      onset of tolerance to salbutamol is not known.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Airway responsiveness as a measure of salbutamol bronchoprotection</measure>
    <time_frame>ten minutes post 200mcg salbutamol on day 1</time_frame>
    <description>Regular use of salbutamol results in loss of bronchoprotection. The primary outcome is to determine the onset of this tolerance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Airway responsiveness as a measure of salbutamol bronchoprotection</measure>
    <time_frame>ten minutes post 200mcg salbutamol on day 3</time_frame>
    <description>Regular use of salbutamol results in loss of bronchoprotection. The primary outcome is to determine the onset of this tolerance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Airway responsiveness as a measure of bronchoprotection. The primary outcome is to determine the onset of this tolerance.</measure>
    <time_frame>ten minutes post 200mcg salbutamol on day 5</time_frame>
    <description>Regular use of salbutamol results in loss of bronchoprotection. The primary outcome is to determine the onset of this tolerance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Airway responsiveness as a measure of salbutamol bronchoprotection</measure>
    <time_frame>ten minutes post 200mcg salbutamol on day 7</time_frame>
    <description>Regular use of salbutamol results in loss of bronchoprotection. The primary outcome is to determine the onset of this tolerance.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>salbutamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>200mcg twice daily for a total of 7 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>salbutamol</intervention_name>
    <description>200mcg twice daily for a total of 7 doses</description>
    <arm_group_label>salbutamol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>200mcg twice a day for a total of 7 doses (3.5 days).</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female

          -  18 to 65 years of age

          -  non smoker

          -  beta agonist naive for at least 14 days

          -  baseline FEV1 at least 70% predicted

          -  no respiratory tract infection or allergen exposure (if atopic) within 4 weeks of
             visit 1

        Exclusion Criteria:

          -  poorly controlled asthma

          -  pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald W Cockcroft, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Saskatchewan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Saskatchewan</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2011</study_first_submitted>
  <study_first_submitted_qc>April 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2011</study_first_posted>
  <last_update_submitted>July 19, 2012</last_update_submitted>
  <last_update_submitted_qc>July 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

